Inclusion Criteria:  Provision of informed consent prior to any study specific procedures. Aged ≥20 years at the time of consent. eGFR ≥10 and ≤30 mL/min/1.73m2 (Modification of Diet in Renal Disease (MDRD) equation ) at randomization. eGFR decline ≥2.5 mL/min/1.73m2 (≥ 3 measurements, simple linear regression) in one year before randomization. Urine albumin-to-creatinine ratio (UACR) 200-5000 mg/g or urine protein-to-creatinine ratio (UPCR) 300-7500 mg/g at least in one measurement in one year before randomization. In the pre-ESRD care and education program of Ministry of Health and Welfare of Taiwan (pre-ESRD program) for ≥3 months before randomization.  Exclusion Criteria:  Lupus nephritis, anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and organ transplantation. Receiving therapy with an SGLT2 inhibitor within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor. Any condition outside the renal and CV disease area, with a life expectancy of less than 2 years based on investigator's clinical judgement. Active malignancy requiring treatment at the time of visit 1. Women of child-bearing potential who are not willing to use a medically accepted method of contraception throughout the study, OR women who have a positive pregnancy test at enrolment OR women who are breast-feeding. Urinary tract obstruction (hydronephrosis, hydroureter and abnormal post-voiding residual urine volume under renal echography). Frequent urosepsis (≥2 times in one year before enrollment) and history of Fournier's gangrene. Inability of the patient, in the opinion of the investigator, to understand and/or comply with treatment, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study.